This prospective multi-cohort observational study evaluates the association between peripheral blood lipidomic and ceramide profiles and atrial fibrillation. The study hypothesis is that peripheral blood lipidomic features and ceramide-related profiles are associated with the presence of atrial fibrillation. Participants with atrial fibrillation and control participants with other cardiovascular diseases will be prospectively enrolled. Peripheral blood samples will be analyzed using untargeted lipidomic profiling in one cohort and targeted ceramide assays in another cohort.
Adults aged 18 years or older.
Participants who are able to provide informed consent.
Participants diagnosed with atrial fibrillation based on Holter monitoring, or control participants with other cardiovascular diseases and no documented atrial fibrillation.
Participants with available peripheral blood samples for untargeted lipidomic profiling or targeted ceramide analysis.
Inability or unwillingness to provide informed consent.
Missing key clinical information.
Missing or poor-quality peripheral blood samples unsuitable for lipidomic or targeted ceramide analysis.
Participants considered unsuitable for this study by the investigators.
The study population includes adult patients prospectively enrolled from clinical cardiovascular cohorts. Participants will include patients with atrial fibrillation diagnosed by Holter monitoring and control patients with other cardiovascular diseases without documented atrial fibrillation. All participants will provide peripheral blood samples for untargeted lipidomic profiling or targeted ceramide analysis.
Case-control
Prospective
Peripheral blood untargeted lipidomic profiling
Other interventionPeripheral blood samples from cohort 1 will be analyzed using untargeted lipidomic profiling. No treatment or therapeutic intervention will be assigned by the investigators.
Peripheral blood targeted ceramide assay
Other interventionPeripheral blood samples from cohort 2 will be analyzed using targeted ceramide assays. No treatment or therapeutic intervention will be assigned by the investigators.
Peripheral Serum Concentration of Cer(d18:1/18:1), nmol/L
The concentration of Cer(d18:1/18:1) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/16:0), nmol/L
The concentration of Cer(d18:1/16:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/18:0), nmol/L
The concentration of Cer(d18:1/18:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Peripheral Serum Concentration of Cer(d18:1/20:0), nmol/L
The concentration of Cer(d18:1/20:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L. Concentrations will be compared between participants with atrial fibrillation and control participants.
Click on the lead sponsor to view all of their trials.
